Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to l-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients

Abstract

OBJECTIVES: L-Theanine (γ-glutamylethylamide) augmentation to antipsychotic therapy ameliorates positive, activation, and anxiety symptoms in schizophrenia and schizoaffective disorder patients. This study examines the association between circulating levels of neurochemical indicators and the beneficial clinical effects of L-theanine augmentation. METHODS: Serum levels of neurochemical indicators such as brain-derived neurotrophic factor (BDNF), dehydroepiandrosterone (DHEA), its sulfate (DHEAS), cortisol, cholesterol, and insulin were monitored in 40 schizophrenia and schizoaffective disorder patients during an 8-week, double-blind, randomized, placebo-controlled trial with L-theanine (400 mg/d). Multiple regression analysis was applied for searching association between improvement in symptom scores and changes in circulating levels of neurochemical indicators for an 8-week trial. RESULTS: Regression models among L-theanine-treated patients indicate that circulating levels of BDNF and cortisol-to-DHEAS*100 molar ratio were significantly associated with the beneficial clinical effects of L-theanine augmentation. Variability of serum BDNF levels accounted for 26.2% of the total variance in reduction of dysphoric mood and 38.2% in anxiety scores. In addition, the changes in cortisol-to-DHEAS*100 molar ratio accounted for 30% to 34% of the variance in activation factor and dysphoric mood scores and for 15.9% in anxiety scores. Regression models among placebo-treated patients did not reach significant level. CONCLUSIONS: These preliminary results indicate that circulating BDNF and cortisol-to-DHEAS*100 molar ratio may be involved in the beneficial clinical effects of L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.

Overview

Integrity signals

Registry

Crossref · 10.1097/wnf.0b013e318220d8c6

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 59 references

Cited by

See all 31

Metadata

Authors
Miodownik, C., Maayan, R., Ratner, Y., Lerner, V., Pintov, L., Mar, M., Weizman, A., & Ritsner, M. S.
Affiliations
  • Ben-Gurion University of the Negev (IL)
  • Sha'ar Menashe Mental Health Center (IL)
  • Tel Aviv University (IL)
  • Technion – Israel Institute of Technology (IL)
Corresponding author
  • Miodownik, Chanoch
  • Lerner, Vladimir
Venue
Clinical Neuropharmacology
Published
2011-07
Volume
34
Issue
4
Pages
155-160
ISSN
0362-5664 (ISSN-L)
OpenAlex
W1975395689
Cited by
31
References
59
Citations by year
2026: 1 · 2025: 1 · 2024: 4 · 2023: 1 · 2022: 1 · 2020: 2 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 2 · 2012: 3
FWCI
1.53
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Neuropharmacology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
theanine, antipsychotic augmentation, schizophrenia, schizoaffective disorder, brain-derived neurotrophic factor, cortisol, dehydroepiandrosterone sulfate, neurochemical markers, dysphoric mood, anxiety symptoms, positive symptoms
MeSH terms
Adult, Algorithms, Anxiety, Double-Blind Method, Drug Therapy, Combination, Female, Glutamates, Humans, Hydrocortisone, Male, Psychiatric Status Rating Scales, Psychotic Disorders, Schizophrenia, Antipsychotic Agents, Biomarkers, Brain-Derived Neurotrophic Factor, Dehydroepiandrosterone Sulfate, Mood Disorders, Diagnostic and Statistical Manual of Mental Disorders, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to l-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients. https://app.cochat.ai/papers/10.1097/wnf.0b013e318220d8c6
The paper
Miodownik, C., Maayan, R., Ratner, Y., Lerner, V., Pintov, L., Mar, M., Weizman, A., & Ritsner, M. S. (2011). Serum Levels of Brain-Derived Neurotrophic Factor and Cortisol to Sulfate of Dehydroepiandrosterone Molar Ratio Associated With Clinical Response to l-Theanine as Augmentation of Antipsychotic Therapy in Schizophrenia and Schizoaffective Disorder Patients. Clinical Neuropharmacology. https://doi.org/10.1097/wnf.0b013e318220d8c6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.